Pharma Reaserch Prod Co Ltd Cash Flow Conversion Efficiency
Pharma Reaserch Prod Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Pharma Reaserch Prod Co Ltd (214450) has a cash flow conversion efficiency ratio of 0.085x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩61.53 Billion ≈ $41.70 Million USD) by net assets (₩723.88 Billion ≈ $490.56 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Pharma Reaserch Prod Co Ltd (2015–2025)
Cash flow conversion efficiency of Pharma Reaserch Prod Co Ltd from 2015 to 2025. This chart illustrates how Pharma Reaserch Prod Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Pharma Reaserch Prod Co Ltd for real-time trading data and today's change.
Pharma Reaserch Prod Co Ltd Cash Flow Conversion Ratio Explained
Pharma Reaserch Prod Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Pharma Reaserch Prod Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pharma Reaserch Prod Co Ltd ranked by their cash flow conversion efficiency. Also see 214450 market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Melco Resorts & Entertainment Ltd
NASDAQ:MLCO
|
-0.046x |
|
Semrush Holdings Inc
NYSE:SEMR
|
0.051x |
|
Xiamen Kingdomway Group Co
SHE:002626
|
0.040x |
|
Altra Fastigheter AB (publ)
ST:ALTRA
|
0.027x |
|
KPIT Technologies Limited
NSE:KPITTECH
|
0.106x |
|
Cury Construtora e Incorporadora S.A
SA:CURY3
|
0.165x |
|
China Tianying Inc
SHE:000035
|
0.013x |
|
Hansol Chemica
KO:014680
|
0.061x |
Annual Cash Flow Conversion Efficiency for Pharma Reaserch Prod Co Ltd (2015–2025)
The table below shows the annual cash flow conversion efficiency of Pharma Reaserch Prod Co Ltd from 2015 to 2025. Review Pharma Reaserch Prod Co Ltd (214450) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩723.88 Billion ≈ $490.56 Million |
₩183.16 Billion ≈ $124.13 Million |
0.253x | +3.01% |
| 2024-12-31 | ₩569.44 Billion ≈ $385.90 Million |
₩139.88 Billion ≈ $94.79 Million |
0.246x | +74.82% |
| 2023-12-31 | ₩462.19 Billion ≈ $313.22 Million |
₩64.95 Billion ≈ $44.01 Million |
0.141x | -18.75% |
| 2022-12-31 | ₩343.50 Billion ≈ $232.79 Million |
₩59.40 Billion ≈ $40.26 Million |
0.173x | -19.11% |
| 2021-12-31 | ₩305.44 Billion ≈ $206.99 Million |
₩65.30 Billion ≈ $44.25 Million |
0.214x | +61.97% |
| 2020-12-31 | ₩245.42 Billion ≈ $166.32 Million |
₩32.39 Billion ≈ $21.95 Million |
0.132x | +43.18% |
| 2019-12-31 | ₩209.07 Billion ≈ $141.69 Million |
₩19.27 Billion ≈ $13.06 Million |
0.092x | +250.09% |
| 2018-12-31 | ₩197.62 Billion ≈ $133.93 Million |
₩5.20 Billion ≈ $3.53 Million |
0.026x | -44.96% |
| 2017-12-31 | ₩178.85 Billion ≈ $121.21 Million |
₩8.56 Billion ≈ $5.80 Million |
0.048x | +0.60% |
| 2016-12-31 | ₩171.64 Billion ≈ $116.32 Million |
₩8.16 Billion ≈ $5.53 Million |
0.048x | -53.49% |
| 2015-12-31 | ₩156.75 Billion ≈ $106.23 Million |
₩16.02 Billion ≈ $10.86 Million |
0.102x | -- |
About Pharma Reaserch Prod Co Ltd
PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly… Read more